Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-015: Calderasib + Durvalumab in KRAS G12C-Mutant NSCLC
NCT07554339Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Primary completion
- Dec 2032
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of calderasib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jun 2026; status: recruiting.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07554339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554339.